TY - JOUR
T1 - Systematic review on the use of patient-reported outcome measures in brain tumor studies
T2 - Part of the Response Assessment in Neuro-Oncology Patient-Reported Outcome (RANO-PRO) initiative
AU - Dirven, Linda
AU - Vos, Maartje E.
AU - Walbert, Tobias
AU - Armstrong, Terri S.
AU - Arons, David
AU - Van Den Bent, Martin J.
AU - Blakeley, Jaishri
AU - Brown, Paul D.
AU - Bulbeck, Helen
AU - Chang, Susan M.
AU - Coens, Corneel
AU - Gilbert, Mark R.
AU - Grant, Robin
AU - Jalali, Rakesh
AU - Leach, Danielle
AU - Leeper, Heather
AU - Mendoza, Tito
AU - Nayak, Lakshmi
AU - Oliver, Kathy
AU - Reijneveld, Jaap C.
AU - Le Rhun, Emilie
AU - Rubinstein, Larry
AU - Weller, Michael
AU - Wen, Patrick Y.
AU - Taphoorn, Martin J.B.
N1 - Publisher Copyright:
© 2021 The Author(s) 2021. Published by Oxford University Press on behalf of the Society for Neuro-Oncology and the European Association of Neuro-Oncology. All rights reserved. For permissions, please e-mail: [email protected].
PY - 2021/8/1
Y1 - 2021/8/1
N2 - Background: The Response Assessment in Neuro-Oncology Patient-Reported Outcome (RANO-PRO) working group aims to provide guidance on the use of PROs in brain tumor patients. PRO measures should be of high quality, both in terms of relevance and other measurement properties. This systematic review aimed to identify PRO measures that have been used in brain tumor studies to date. Methods: A systematic literature search for articles published up to June 25, 2020 was conducted in several electronic databases. Pre-specified inclusion criteria were used to identify studies using PRO measures assessing symptoms, (instrumental) activities of daily living [(I)ADL] or health-related quality of life (HRQoL) in adult patients with glioma, meningioma, primary central nervous system lymphoma, or brain metastasis. Results: A total of 215 different PRO measures were identified in 571 published and 194 unpublished studies. The identified PRO measures include brain tumor-specific, cancer-specific, and generic instruments, as well as instruments designed for other indications or multi- or single-item study-specific questionnaires. The most frequently used instruments were the EORTC QLQ-C30 and QLQ-BN20 (n = 286 and n = 247), and the FACT-Br (n = 167), however, the majority of the instruments were used only once or twice (150/215). Conclusion: Many different PRO measures assessing symptoms, (I)ADL or HRQoL have been used in brain tumor studies to date. Future research should clarify whether these instruments or their scales/items exhibit good content validity and other measurement properties for use in brain tumor patients.
AB - Background: The Response Assessment in Neuro-Oncology Patient-Reported Outcome (RANO-PRO) working group aims to provide guidance on the use of PROs in brain tumor patients. PRO measures should be of high quality, both in terms of relevance and other measurement properties. This systematic review aimed to identify PRO measures that have been used in brain tumor studies to date. Methods: A systematic literature search for articles published up to June 25, 2020 was conducted in several electronic databases. Pre-specified inclusion criteria were used to identify studies using PRO measures assessing symptoms, (instrumental) activities of daily living [(I)ADL] or health-related quality of life (HRQoL) in adult patients with glioma, meningioma, primary central nervous system lymphoma, or brain metastasis. Results: A total of 215 different PRO measures were identified in 571 published and 194 unpublished studies. The identified PRO measures include brain tumor-specific, cancer-specific, and generic instruments, as well as instruments designed for other indications or multi- or single-item study-specific questionnaires. The most frequently used instruments were the EORTC QLQ-C30 and QLQ-BN20 (n = 286 and n = 247), and the FACT-Br (n = 167), however, the majority of the instruments were used only once or twice (150/215). Conclusion: Many different PRO measures assessing symptoms, (I)ADL or HRQoL have been used in brain tumor studies to date. Future research should clarify whether these instruments or their scales/items exhibit good content validity and other measurement properties for use in brain tumor patients.
KW - activities of daily living
KW - brain tumor
KW - health-related quality of life
KW - patient-reported outcome
KW - symptoms
UR - http://www.scopus.com/inward/record.url?scp=85111860395&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85111860395&partnerID=8YFLogxK
U2 - 10.1093/nop/npab013
DO - 10.1093/nop/npab013
M3 - Article
C2 - 34277020
AN - SCOPUS:85111860395
SN - 2054-2577
VL - 8
SP - 417
EP - 425
JO - Neuro-Oncology Practice
JF - Neuro-Oncology Practice
IS - 4
ER -